Quality documentation concerning biological investigational medicinal products in clinical trials
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
On 3 May, the European Comission published the "Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials".
The guideline is related to proteins and polypeptides, their derivatives and products of which they are components and addresses the specific documentation requirements on the biological, chemical and pharmaceutical quality of IMPs containing biological / biotechnology derived substances in cases where no 'simplified IMPD' is submitted.
Amongst others, the document includes in its first part necessary information on manufacturing, characterisation, reference standards and stability of active substances as well as investigational medicinal products currently tested. The second part are four appendices with the focus on
- Facilities and Equipement
- Adventitious agents safety evaluation
- Excipients
- Solvents for reconstitution and diluents
The third part of the guideline covers a non-exhaustive list of typically 'substantial' amendments.
Please see the complete "Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials".
Author
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development